Annexin A2 contributes to cisplatin resistance by activation of JNK-p53 pathway in non-small cell lung cancer cells

BACKGROUND: Development of resistance to therapy continues to be a serious clinical problem in lung cancer management. We previously identified that Annexin A2 is significantly up-regulated in cisplatin-resistant non-small cell lung cancer (NSCLC) A549/DDP cells. However, the exact function and mole...

Descripción completa

Detalles Bibliográficos
Autores principales: Feng, Xiaomin, Liu, Hao, Zhang, Zhijie, Gu, Yixue, Qiu, Huisi, He, Zhimin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591524/
https://www.ncbi.nlm.nih.gov/pubmed/28886730
http://dx.doi.org/10.1186/s13046-017-0594-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591524/
https://www.ncbi.nlm.nih.gov/pubmed/28886730
http://dx.doi.org/10.1186/s13046-017-0594-1

Ejemplares similares